About NGM Biopharmaceuticals
NGM Biopharmaceuticals focuses on discovering and developing new medicines for patients with serious diseases. The company uses a biology-centric approach to drug discovery, which combines an understanding of complex disease biology with protein engineering to create unique insights. These insights help NGM Bio develop promising drug candidates that can quickly move into early testing phases. Unlike many competitors, all of NGM Bio's therapeutic candidates come from its own research efforts, ensuring a strong connection between discovery and development. The company's goal is to address unmet medical needs by advancing its drug candidates through clinical development and eventually bringing them to market.
South San Francisco, CaliforniaHeadquarters
2008Year Founded
$406.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Merger with The Column Group may disrupt ongoing projects or alter focus areas.
Focus on rare diseases may limit market size and revenue potential.
Workforce reduction by 33% could impact operational capabilities and trial progress.
Differentiation
NGM Bio focuses on rare diseases with significant unmet needs, like PSC and HG.
Their biology-centric drug discovery integrates complex disease biology with protein engineering.
All therapeutic candidates originate from NGM Bio's in-house discovery efforts.
Upsides
FDA's Orphan Drug Designation for aldafermin could expedite its development and approval.
$122 million Series A financing strengthens NGM Bio's financial position for clinical trials.
Positive Phase 2b results for aldafermin in NASH cirrhosis support its therapeutic potential.
Funding
Total raised$406.11 M
Latest valuation$135.00 M
StageIPO
GROWTH EQUITY VC
6/30/2024$122
ACQUISITION
1/31/2024$135
$135.00 MPOST IPO EQUITY
12/31/2020$125
SERIES D
2/28/2015$58
$287.50 MSERIES E
2/28/2015$106
$530.00 MSERIES C
6/30/2013$50
$250.00 MSERIES B
10/31/2011$55
$277.00 MSERIES A
11/30/2009$27
$133.00 M